Kodiak Sciences Inc
NASDAQ:KOD
Intrinsic Value
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company. [ Read More ]
The intrinsic value of one KOD stock under the Base Case scenario is 1.78 USD. Compared to the current market price of 3.38 USD, Kodiak Sciences Inc is Overvalued by 47%.
Valuation Backtest
Kodiak Sciences Inc
Run backtest to discover the historical profit from buying and selling KOD stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Kodiak Sciences Inc
Current Assets | 289.3m |
Cash & Short-Term Investments | 285.5m |
Other Current Assets | 3.8m |
Non-Current Assets | 190.1m |
PP&E | 175m |
Other Non-Current Assets | 15m |
Current Liabilities | 41.7m |
Accounts Payable | 13.6m |
Accrued Liabilities | 28.1m |
Non-Current Liabilities | 171.9m |
Other Non-Current Liabilities | 171.9m |
Earnings Waterfall
Kodiak Sciences Inc
Revenue
|
0
USD
|
Operating Expenses
|
-277.3m
USD
|
Operating Income
|
-277.3m
USD
|
Other Expenses
|
16.8m
USD
|
Net Income
|
-260.5m
USD
|
Free Cash Flow Analysis
Kodiak Sciences Inc
KOD Profitability Score
Profitability Due Diligence
Kodiak Sciences Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Kodiak Sciences Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
KOD Solvency Score
Solvency Due Diligence
Kodiak Sciences Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
Kodiak Sciences Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
KOD Price Targets Summary
Kodiak Sciences Inc
According to Wall Street analysts, the average 1-year price target for KOD is 4.34 USD with a low forecast of 2.02 USD and a high forecast of 7.35 USD.
Ownership
KOD Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
KOD Price
Kodiak Sciences Inc
Average Annual Return | 200.71% |
Standard Deviation of Annual Returns | 425.4% |
Max Drawdown | -99% |
Market Capitalization | 177.5m USD |
Shares Outstanding | 52 508 600 |
Percentage of Shares Shorted | 6.33% |
KOD News
Last Important Events
Kodiak Sciences Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Kodiak Sciences Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Palo Alto, California and currently employs 93 full-time employees. The company went IPO on 2018-10-04. The Company’s Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies. The Company’s lead product candidate includes KSI-301, which is an antibody biopolymer conjugate being investigated in multiple pivotal studies in retinal vascular diseases, including wAMD, DME, RVO and non-proliferative diabetic retinopathy. KSI-301 is under Phase IIb/III clinical trials. The Company’s other pipeline candidates includes product candidates KSI-501 and KSI-601, which are developed for the treatment of other unmet needs in retina, such as dry AMD and glaucoma. The Company’s subsidiary includes Kodiak Sciences GmbH.
Contact
IPO
Employees
Officers
The intrinsic value of one KOD stock under the Base Case scenario is 1.78 USD.
Compared to the current market price of 3.38 USD, Kodiak Sciences Inc is Overvalued by 47%.